Exelixis
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The last earnings update was 25 days ago. More info.
Add to Portfolio Compare Print
EXEL Share Price and Events
7 Day Returns
1 Year Returns
EXEL Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Exelixis (EXEL) | 5.3% | -0.9% | -9% | -2.3% | 221.1% | 515.1% |
| US Biotechs | 0.3% | -2.6% | -6% | -4.8% | 3.6% | 11% |
| US Market | -1.4% | -3.9% | 0.1% | 1.6% | 33.2% | 38.2% |
1 Year Return vs Industry and Market
- EXEL outperformed the Biotechs industry which returned -4.8% over the past year.
- EXEL underperformed the Market in United States of America which returned 1.6% over the past year.
Value
Is Exelixis undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
Exelixis
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for Exelixis.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 14 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 10.2% |
| Perpetual Growth Rate | 10-Year US Government Bond Rate | 2.7% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year US Govt Bond Rate | 2.7% |
| Equity Risk Premium | S&P Global | 6% |
| Biotechs Unlevered Beta | Simply Wall St/ S&P Global | 1.38 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.384 (1 + (1- 21%) (0.32%)) |
1.259 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
1.26 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.259 * 5.96%) |
10.24% |
Discounted Cash Flow Calculation for NasdaqGS:EXEL using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Exelixis is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (USD, Millions) | Source |
Present Value Discounted (@ 10.24%) |
|
|---|---|---|---|
| 2019 | 278.43 | Analyst x2 | 252.57 |
| 2020 | 546.10 | Analyst x2 | 449.39 |
| 2021 | 218.50 | Analyst x1 | 163.10 |
| 2022 | 374.79 | Analyst x1 | 253.80 |
| 2023 | 516.86 | Analyst x1 | 317.50 |
| 2024 | 527.09 | Est @ 1.98% | 293.72 |
| 2025 | 538.70 | Est @ 2.2% | 272.32 |
| 2026 | 551.43 | Est @ 2.36% | 252.86 |
| 2027 | 565.06 | Est @ 2.47% | 235.06 |
| 2028 | 579.47 | Est @ 2.55% | 218.66 |
| Present value of next 10 years cash flows | $2,708.99 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= $579.47 × (1 + 2.73%) ÷ (10.24% – 2.73%) |
$7,930.39 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= $7,930.39 ÷ (1 + 10.24%)10 |
$2,992.56 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= $2,708.99 + $2,992.56 |
$5,701.56 |
| Equity Value per Share (USD) |
= Total value / Shares Outstanding
= $5,701.56 / 301.77 |
$18.89 |
| Calculation | Result | |
|---|---|---|
| Value per share (USD) | From above. | $18.89 |
| Current discount | Discount to share price of
$20.36
= -1 x ($20.36 - $18.89) / $18.89 |
-7.8% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
- The current share price of Exelixis is above its future cash flow value.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Exelixis's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Exelixis's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2019-03-31) in USD | $2.17 |
| NasdaqGS:EXEL Share Price ** | NasdaqGS (2019-05-24) in USD | $20.36 |
| United States of America Biotechs Industry PE Ratio | Median Figure of 35 Publicly-Listed Biotechs Companies | 18.23x |
| United States of America Market PE Ratio | Median Figure of 3,086 Publicly-Listed Companies | 17.45x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Exelixis.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NasdaqGS:EXEL Share Price ÷ EPS (both in USD) = 20.36 ÷ 2.17 |
9.36x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Exelixis is good value based on earnings compared to the US Biotechs industry average.
- Exelixis is good value based on earnings compared to the United States of America market.
Price based on expected Growth
Does
Exelixis's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | 9.36x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 14 Analysts |
17.1%per year |
| United States of America Biotechs Industry PEG Ratio | Median Figure of 28 Publicly-Listed Biotechs Companies | 1.14x |
| United States of America Market PEG Ratio | Median Figure of 2,121 Publicly-Listed Companies | 1.51x |
*Line of best fit is calculated by linear regression .
| Calculation | Outcome | |
|---|---|---|
| PEG Ratio | = PE Ratio ÷ Net Income Annual Growth Rate = 9.36x ÷ 17.1% |
0.55x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Exelixis is good value based on expected growth next year.
Price based on value of assets
What value do investors place on
Exelixis's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2019-03-31) in USD | $4.59 |
| NasdaqGS:EXEL Share Price * | NasdaqGS (2019-05-24) in USD | $20.36 |
| United States of America Biotechs Industry PB Ratio | Median Figure of 415 Publicly-Listed Biotechs Companies | 3.16x |
| United States of America Market PB Ratio | Median Figure of 5,208 Publicly-Listed Companies | 1.8x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NasdaqGS:EXEL Share Price ÷ Book Value per Share (both in USD) = 20.36 ÷ 4.59 |
4.43x |
* Primary Listing of Exelixis.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Exelixis is overvalued based on assets compared to the US Biotechs industry average.
Value checks
We assess Exelixis's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check) Exelixis has a total score of 3/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
Future Performance
How is Exelixis expected to perform in the next 1 to 3 years based on estimates from 14 analysts?
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Exelixis's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
- Exelixis's earnings growth is expected to exceed the United States of America market average.
- Exelixis's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| NasdaqGS:EXEL Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 14 Analysts | 17.1% |
| NasdaqGS:EXEL Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 14 Analysts | 15.2% |
| United States of America Biotechs Industry Earnings Growth Rate | Market Cap Weighted Average | 22.6% |
| United States of America Biotechs Industry Revenue Growth Rate | Market Cap Weighted Average | 17.7% |
| United States of America Market Earnings Growth Rate | Market Cap Weighted Average | 13.7% |
| United States of America Market Revenue Growth Rate | Market Cap Weighted Average | 7.3% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (1 month ago) | See Below |
| Future Estimates | Average of up to 14 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 1,660 | 871 | 703 | 6 |
| 2022-12-31 | 1,508 | 789 | 582 | 8 |
| 2021-12-31 | 1,275 | 653 | 466 | 11 |
| 2020-12-31 | 1,111 | 526 | 386 | 14 |
| 2019-12-31 | 919 | 390 | 297 | 14 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2019-03-31 | 856 | 506 | 650 |
| 2018-12-31 | 854 | 416 | 690 |
| 2018-09-30 | 745 | 364 | 368 |
| 2018-06-30 | 672 | 238 | 323 |
| 2018-03-31 | 585 | 169 | 253 |
| 2017-12-31 | 452 | 166 | 154 |
| 2017-09-30 | 410 | 197 | 150 |
| 2017-06-30 | 320 | 154 | 58 |
| 2017-03-31 | 257 | 122 | 6 |
| 2016-12-31 | 191 | 210 | -70 |
| 2016-09-30 | 124 | 90 | -147 |
| 2016-06-30 | 71 | 61 | -181 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (1 month ago) | See Below |
| Future Estimates | Average of up to 14 Analyst Estimates (S&P Global) | See Below |
All data from Exelixis Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 2.14 | 2.46 | 1.45 | 6.00 |
| 2022-12-31 | 1.78 | 2.23 | 1.25 | 8.00 |
| 2021-12-31 | 1.45 | 1.87 | 0.77 | 9.00 |
| 2020-12-31 | 1.22 | 1.59 | 0.63 | 12.00 |
| 2019-12-31 | 0.95 | 1.17 | 0.77 | 12.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2019-03-31 | 2.17 |
| 2018-12-31 | 2.32 |
| 2018-09-30 | 1.24 |
| 2018-06-30 | 1.09 |
| 2018-03-31 | 0.86 |
| 2017-12-31 | 0.52 |
| 2017-09-30 | 0.52 |
| 2017-06-30 | 0.21 |
| 2017-03-31 | 0.02 |
| 2016-12-31 | -0.28 |
| 2016-09-30 | -0.62 |
| 2016-06-30 | -0.80 |
*GAAP earnings excluding extraordinary items.
Future performance checks
We assess Exelixis's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Exelixis has a total score of 4/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
Past Performance
How has Exelixis performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Exelixis has delivered over 20% year on year earnings growth in the past 5 years.
- Exelixis's 1-year earnings growth exceeds its 5-year average (156.8% vs 73.6%)
- Exelixis's earnings growth has exceeded the US Biotechs industry average in the past year (156.8% vs 54.9%).
Earnings and Revenue History
All data from Exelixis Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2019-03-31 | 855.59 | 649.99 | 212.49 | 207.79 |
| 2018-12-31 | 853.83 | 690.07 | 206.37 | 182.26 |
| 2018-09-30 | 745.30 | 368.47 | 200.27 | 157.19 |
| 2018-06-30 | 672.41 | 322.97 | 190.28 | 140.99 |
| 2018-03-31 | 585.31 | 253.07 | 179.09 | 126.72 |
| 2017-12-31 | 452.48 | 153.86 | 159.36 | 112.17 |
| 2017-09-30 | 409.99 | 150.49 | 126.09 | 103.77 |
| 2017-06-30 | 319.67 | 58.08 | 120.42 | 95.48 |
| 2017-03-31 | 256.91 | 5.64 | 115.58 | 90.25 |
| 2016-12-31 | 191.45 | -70.22 | 116.15 | 95.97 |
| 2016-09-30 | 123.81 | -146.91 | 120.29 | 95.64 |
| 2016-06-30 | 71.47 | -181.17 | 105.67 | 101.47 |
| 2016-03-31 | 43.21 | -185.80 | 82.63 | 103.00 |
| 2015-12-31 | 37.17 | -161.74 | 57.31 | 96.35 |
| 2015-09-30 | 34.59 | -178.13 | 49.93 | 112.53 |
| 2015-06-30 | 31.02 | -195.15 | 41.99 | 130.07 |
| 2015-03-31 | 29.59 | -229.09 | 45.67 | 156.54 |
| 2014-12-31 | 25.11 | -261.30 | 50.83 | 189.10 |
| 2014-09-30 | 22.11 | -281.34 | 54.70 | 199.05 |
| 2014-06-30 | 21.28 | -285.90 | 58.39 | 202.77 |
| 2014-03-31 | 26.57 | -274.65 | 55.10 | 200.88 |
| 2013-12-31 | 31.34 | -244.76 | 50.96 | 178.76 |
| 2013-09-30 | 34.81 | -226.21 | 47.15 | 161.66 |
| 2013-06-30 | 42.65 | -191.90 | 40.90 | 144.98 |
| 2013-03-31 | 38.61 | -166.22 | 34.48 | 128.52 |
| 2012-12-31 | 47.45 | -147.65 | 31.84 | 128.88 |
| 2012-09-30 | 132.94 | -49.16 | 29.02 | 127.16 |
| 2012-06-30 | 247.90 | 61.52 | 29.85 | 133.95 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- Exelixis made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%).
- Exelixis used its assets more efficiently than the US Biotechs industry average last year based on Return on Assets.
- Exelixis has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
Past performance checks
We assess Exelixis's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Exelixis has a total score of 6/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
Health
How is Exelixis's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Exelixis's finances.
The net worth of a company is the difference between its assets and liabilities.
- Exelixis is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Exelixis's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is covered by short term assets, assets are 47.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Exelixis Company Filings, last reported 1 month ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2019-03-31 | 1,385.02 | 19.96 | 799.65 |
| 2018-12-31 | 1,287.45 | 14.97 | 693.33 |
| 2018-09-30 | 915.97 | 14.98 | 634.62 |
| 2018-06-30 | 774.97 | 21.35 | 499.92 |
| 2018-03-31 | 669.77 | 0.00 | 426.92 |
| 2017-12-31 | 284.96 | 15.48 | 387.77 |
| 2017-09-30 | 238.72 | 0.00 | 367.10 |
| 2017-06-30 | 148.51 | 0.00 | 349.26 |
| 2017-03-31 | 119.75 | 113.35 | 424.27 |
| 2016-12-31 | 89.32 | 189.12 | 419.80 |
| 2016-09-30 | 32.02 | 190.86 | 319.68 |
| 2016-06-30 | -186.13 | 396.06 | 328.12 |
| 2016-03-31 | -155.95 | 388.66 | 322.12 |
| 2015-12-31 | -140.81 | 417.94 | 167.06 |
| 2015-09-30 | -74.23 | 377.89 | 197.81 |
| 2015-06-30 | -188.19 | 371.23 | 76.60 |
| 2015-03-31 | -146.76 | 368.43 | 107.25 |
| 2014-12-31 | -114.83 | 356.97 | 144.29 |
| 2014-09-30 | -58.51 | 355.22 | 192.00 |
| 2014-06-30 | 3.24 | 348.97 | 233.52 |
| 2014-03-31 | 71.48 | 343.02 | 273.57 |
| 2013-12-31 | 66.24 | 347.24 | 242.45 |
| 2013-09-30 | 132.76 | 341.59 | 279.22 |
| 2013-06-30 | 196.33 | 336.14 | 351.97 |
| 2013-03-31 | 254.85 | 330.85 | 356.56 |
| 2012-12-31 | 296.43 | 335.74 | 411.44 |
| 2012-09-30 | 340.85 | 335.29 | 472.35 |
| 2012-06-30 | 99.05 | 182.70 | 207.04 |
- Exelixis's level of debt (1.4%) compared to net worth is satisfactory (less than 40%).
- The level of debt compared to net worth has been reduced over the past 5 years (485% vs 1.4% today).
- Debt is well covered by operating cash flow (2532.8%, greater than 20% of total debt).
- Exelixis earns more interest than it pays, coverage of interest payments is not a concern.
Financial health checks
We assess Exelixis's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Exelixis has a total score of 6/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
Dividends
What is Exelixis's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
$2,000 of
Exelixis
shares you are expected to receive
$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Exelixis's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Exelixis's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 14 Analyst Estimates (S&P Global) | See Below |
| Global Biotechs Industry Average Dividend Yield | Market Cap Weighted Average of 19 Stocks | 2.4% |
| United States of America Market Average Dividend Yield | Market Cap Weighted Average of 2007 Stocks | 2.5% |
| United States of America Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| United States of America Bottom 25% Dividend Yield | 25th Percentile | 1.5% |
| United States of America Top 25% Dividend Yield | 75th Percentile | 3.8% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-12-31 | ||
| 2022-12-31 | ||
| 2021-12-31 | 0.00 | 1.00 |
| 2020-12-31 | 0.00 | 1.00 |
| 2019-12-31 | 0.00 | 1.00 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Exelixis has not reported any payouts.
- Unable to verify if Exelixis's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Exelixis's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Exelixis afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Exelixis has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
Management
CEO
| COMPENSATION | $7,977,535 |
| AGE | 57 |
| TENURE AS CEO | 8.8 years |
CEO Bio
Dr. Michael M. Morrissey, Ph.D., has been the Chief Executive Officer and President of Exelixis, Inc. since July 2010. Dr. Morrissey served as the President of Research and Development at Exelixis Inc. since January 4, 2007 until July 2010. Dr. Morrissey served as an Executive Vice President of Discovery of Exelixis Inc., from January 2006 to December 2006 and its Senior Vice President of Discovery Research from January 2003 to December 2005. Dr. Morrissey served as Vice President of Discovery Research of Exelixis Inc. from February 2000 to December 2002. Dr. Morrissey served as Vice President of Discovery Research, where he was responsible for all aspects of drug discovery from 1991 to 2000 and Director of Pharmaceutical Discovery and Unit Head of Medicinal Chemistry of Berlex Biosciences, a pharmaceutical company. Dr. Morrissey led the effort to expand and modernize the drug discovery capabilities at Berlex through the application of high-throughput screening, combinatorial and medicinal chemistry and structural biology. Dr. Morrissey served as a Senior Scientist and Project Team Leader in Medicinal Chemistry of CIBA-Geigy Corporation, a pharmaceutical company from 1986 to 1991. Over the past nineteen years, Dr. Morrissey has led discovery efforts that identified 13 clinical candidates, including four that have advanced to Phase 2 clinical trials for a variety of cardiovascular and inflammatory indications. He has been a Director at Exelixis, Inc. since July 2010. Dr. Morrissey serves as Member of the Scientific Advisory Board of Resolvyx Pharmaceuticals, Inc. He is the author of numerous scientific publications in medicinal chemistry and drug discovery and an inventor on 68 issued U.S. patents and 25 additional published U.S. patent applications. Dr. Morrissey holds Ph.D. in Chemistry from Harvard University and his B.S. Honors in Chemistry from the University of Wisconsin.
CEO Compensation
- Michael's compensation has been consistent with company performance over the past year, both up more than 20%.
- Michael's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the Exelixis management team in years:
- The tenure for the Exelixis management team is about average.
Management Team
Stelios Papadopoulos
Co-Founder & Chairman
$421K
70
Michael Morrissey
CEO, President & Director
$8M
57
8.8 yrs
Chris Senner
Executive VP & CFO
$3M
50
3.8 yrs
Peter Lamb
Executive VP of Scientific Strategy & Chief Scientific Officer
$3M
57
12.3 yrs
Jeffrey Hessekiel
Executive VP
$3M
49
5.3 yrs
Gisela Schwab
President of Product Development & Medical Affairs and Chief Medical Officer
$4M
61
13.3 yrs
Dana Aftab
Executive Vice President of Business Operations
3.3 yrs
Susan Hubbard
Executive Vice President of Public Affairs & Investor Relations
2.4 yrs
Jon Berndt
Vice President of Sales
3.7 yrs
Gregg Bernier
Vice President of Marketing
3.7 yrs
Board of Directors Tenure
Average tenure and age of the Exelixis board of directors in years:
- The average tenure for the Exelixis board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors
Michael Morrissey
CEO, President & Director
$8M
57
8.8 yrs
Charlie Cohen
Independent Director
$409K
67
23.5 yrs
Stelios Papadopoulos
Co-Founder & Chairman
$421K
70
21.3 yrs
Jack Wyszomierski
Independent Director
$406K
62
15.3 yrs
George Poste
Independent Director
$396K
74
14.8 yrs
Alan Garber
Independent Director
$391K
62
14.3 yrs
Lance Willsey
Independent Director
$385K
56
22.1 yrs
George Scangos
Independent Director
$376K
70
22.6 yrs
Vincent Marchesi
Independent Director
$391K
82
18 yrs
José Baselga
Member of Scientific Advisory Board
58
12.3 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price ($) | Value ($) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 11. May 19 | Sell | Lance Willsey | Individual | 08. May 19 | 08. May 19 | -50,000 | $20.36 | $-1,018,000 | ||
| 04. May 19 | Sell | Christopher Senner | Individual | 03. May 19 | 03. May 19 | -36,261 | $20.70 | $-750,603 | ||
| 28. Feb 19 | Sell | Patrick Haley | Individual | 25. Feb 19 | 25. Feb 19 | -4,272 | $22.27 | $-95,137 | ||
| 20. Feb 19 | Sell | Charles Cohen | Individual | 14. Feb 19 | 19. Feb 19 | -248,180 | $22.41 | $-5,494,906 | ||
| 01. Dec 18 | Sell | Jeffrey Hessekiel | Individual | 28. Nov 18 | 30. Nov 18 | -14,818 | $19.91 | $-285,290 | ||
| 01. Dec 18 | Sell | Christopher Senner | Individual | 30. Nov 18 | 30. Nov 18 | -8,791 | $19.70 | $-173,183 | ||
| 10. Nov 18 | Sell | Patrick Haley | Individual | 07. Nov 18 | 07. Nov 18 | -20,000 | $17.32 | $-346,400 | ||
| 26. Sep 18 | Sell | George Scangos | Individual | 24. Sep 18 | 24. Sep 18 | -25,000 | $16.85 | $-421,250 | ||
| 08. Aug 18 | Sell | Patrick Haley | Individual | 06. Aug 18 | 06. Aug 18 | -2,361 | $20.92 | $-49,392 | ||
| 02. Jun 18 | Sell | Jeffrey Hessekiel | Individual | 31. May 18 | 31. May 18 | -65,000 | $20.71 | $-1,346,150 | ||
| 02. Jun 18 | Sell | Carl Feldbaum | Individual | 30. May 18 | 30. May 18 | -19,512 | $20.60 | $-401,947 | ||
Management checks
We assess Exelixis's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Exelixis has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
News
Simply Wall St News
Exelixis, Inc. (NASDAQ:EXEL) Delivered A Better ROE Than Its Industry
The formula for ROE is: Return on Equity = Net Profit ÷ Shareholders' Equity Or for Exelixis: 47% = US$650m ÷ US$1.4b (Based on the trailing twelve months to March 2019.) Most know that net profit is the total earnings after all expenses, but the concept of shareholders' equity is a little more complicated. … The Importance Of Debt To Return On Equity Companies usually need to invest money to grow their profits. … In my book the highest quality companies have high return on equity, despite low debt.
Simply Wall St - – Full articleHere's What Exelixis, Inc.'s (NASDAQ:EXEL) P/E Ratio Is Telling Us
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). … Looking at earnings over the last twelve months, Exelixis has a P/E ratio of 9.56. … Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS)
Simply Wall St - – Full articleHere's Why We Think Exelixis (NASDAQ:EXEL) Is Well Worth Watching
If, on the other hand, you like companies that have revenue, and even earn profits, then you may well be interested in Exelixis (NASDAQ:EXEL). … Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth. … Exelixis shareholders can take confidence from the fact that EBIT margins are up from 37% to 52%, and revenue is growing.
Simply Wall St - – Full articleNeed To Know: Exelixis, Inc. (NASDAQ:EXEL) Insiders Have Been Selling Shares
In the last twelve months, the biggest single sale by an insider was when the Independent Director, Charles Cohen, sold US$5.5m worth of shares at a price of US$22.41 per share. … That means that even when the share price was below the current price of US$23.57, an insider wanted to cash in some shares. … As a general rule we consider it to be discouraging when insiders are selling below the current price, because it suggests they were happy with a lower valuation.
Simply Wall St - – Full articleIs Exelixis, Inc.'s (NASDAQ:EXEL) Liquidity Good Enough?
Today we will look at EXEL’s financial liquidity and debt levels, which are strong indicators for whether the company can weather economic downturns or fund strategic acquisitions for future growth. … Note that this commentary is very high-level and solely focused on financial health, so I suggest you dig deeper yourself. … Does EXEL Produce Much Cash Relative To Its Debt?
Simply Wall St - – Full articleHow Should Investors Feel About Exelixis, Inc.'s (NASDAQ:EXEL) CEO Pay?
This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Michael Morrissey's Compensation Compare With Similar Sized Companies. … has a market capitalization of US$7.1b, and pays its CEO total annual compensation worth US$9.4m.
Simply Wall St - – Full articleDid The Underlying Business Drive Exelixis's Lovely 491% Share Price Gain?
It's also good to see the share price up 14% over the last quarter. … In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. … One flawed but reasonable way to assess how sentiment around a company has changed, is to compare the earnings per share (EPS) with the share price.
Simply Wall St - – Full articleWhy Exelixis, Inc. (NASDAQ:EXEL) Looks Like A Quality Company
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. … That means that for every $1 worth of shareholders' equity, it generated $0.40 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity
Simply Wall St - – Full articleHere's What Exelixis, Inc.'s (NASDAQ:EXEL) P/E Ratio Is Telling Us
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). … Exelixis has a price to earnings ratio of 18.77, based on the last twelve months. … Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS)
Simply Wall St - – Full articleAn Examination Of Exelixis, Inc. (NASDAQ:EXEL)
(NASDAQ:EXEL) is a company with exceptional fundamental characteristics. … Upon building up an investment case for a stock, we should look at various aspects. … In the case of EXEL, it
Simply Wall St - – Full articleCompany Info
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company’s products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. Exelixis, Inc. has collaboration and license agreement with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Merck, Invenra, Inc., StemSynergy Therapeutics, Inc., and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.
Details
| Name: | Exelixis, Inc. |
| EXEL | |
| Exchange: | NasdaqGS |
| Founded: | 1994 |
| $6,143,983,368 | |
| 301,767,356 | |
| Website: | http://www.exelixis.com |
| Address: |
Exelixis, Inc. 1851 Harbor Bay Parkway, Alameda, California, 94502, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NasdaqGS | EXEL | Common Stock | Nasdaq Global Select | US | USD | 11. Apr 2000 | |
| DB | EX9 | Common Stock | Deutsche Boerse AG | DE | EUR | 11. Apr 2000 | |
| LSE | 0IJO | Common Stock | London Stock Exchange | GB | USD | 11. Apr 2000 |
Number of employees
Current staff
Industry
| Biotechnology | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/05/26 23:36 |
| End of day share price update: | 2019/05/24 00:00 |
| Last estimates confirmation: | 2019/05/16 |
| Last earnings filing: | 2019/05/01 |
| Last earnings reported: | 2019/03/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
